August 2015 Supplement - Endovascular Today

Table of Contents

Supplement

August 2015 Supplement

The Evolution of SFA Care: The DCB Paradigm Shift

An in-depth look at how the science and clinical use of the first FDA-approved drug-coated balloon, LUTONIX® 035, continues to advance the treatment of PAD.

Sponsored by Bard Peripheral Vascular, Inc.

Issue

Global Perspectives on SFA Treatment

Experts from around the world describe the current interventional climate in their respective regions.

View Issue

In This Supplement

Download PDF

Drug-Coated Balloons: The Future Ahead

Experts weigh in on the ongoing trial data supporting the use of drug-coated balloons.

By J.A. Mustapha, MD; Patrick J. Geraghty, MD; Carlos Mena, MD; and Scott Trerotola, MD

Treatment Algorithms: This Is How I Use a DCB

An expert panel discusses the current role, data, and techniques for the use of drug-coated balloons in tackling PAD.

By J.A. Mustapha, MD; Chad R. Laurich, MD; Lawrence A. Garcia, MD; Patrick J. Geraghty, MD; and Prakash Krishnan, MD

Safety of Drug-Coated Balloons: Insight from Preclinical Studies

Understanding the advantages and disadvantages that can result from different balloon technologies on the market.

By Kazuyuki Yahagi, MD; Frank D. Kolodgie, PhD; and Renu Virmani, MD

The Economic Impact of Drug-Coated Balloons in the SFA

From a financial standpoint, DCBs have become the most attractive endovascular option for treating atherosclerosis in the superficial femoral artery.

By Mark W. Burket, MD

The Role of SFA Stenting in the DCB Era

How will drug-coated balloons change the role of stenting in the SFA?

By Constantino S. Peñ,a, MD

Latest Issues

April 2026

March 2026

February 2026

January 2026

December 2025

View All Issues

In This Supplement

Most Read Articles